Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Assets Average (2022 - 2025)

Historic Assets Average for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $35.3 million.

  • BioXcel Therapeutics' Assets Average fell 3826.39% to $35.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.3 million, marking a year-over-year decrease of 3826.39%. This contributed to the annual value of $56.0 million for FY2024, which is 5992.2% down from last year.
  • As of Q3 2025, BioXcel Therapeutics' Assets Average stood at $35.3 million, which was down 3826.39% from $32.2 million recorded in Q2 2025.
  • BioXcel Therapeutics' Assets Average's 5-year high stood at $246.5 million during Q3 2022, with a 5-year trough of $32.2 million in Q2 2025.
  • Over the past 4 years, BioXcel Therapeutics' median Assets Average value was $82.5 million (recorded in 2023), while the average stood at $115.8 million.
  • Examining YoY changes over the last 5 years, BioXcel Therapeutics' Assets Average showed a top increase of 3028.22% in 2023 and a maximum decrease of 6135.74% in 2023.
  • Over the past 4 years, BioXcel Therapeutics' Assets Average (Quarter) stood at $225.3 million in 2022, then tumbled by 61.36% to $87.1 million in 2023, then tumbled by 49.91% to $43.6 million in 2024, then dropped by 19.09% to $35.3 million in 2025.
  • Its last three reported values are $35.3 million in Q3 2025, $32.2 million for Q2 2025, and $38.5 million during Q1 2025.